Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema versus placebo in adults with overweight or obesity
2020-005435-75Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of CagriSema, cagrilintide and semaglutide in obesity and Overweight (2 arms), sponsored by Novo Nordisk. Primary endpoint: Relative change in body weight. Started May 2022; status: active.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2020-005435-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005435-75.